Corroborating the effectivity of mitigating IL-1β activity in human atherosclerosis, depleting IL-1β genetically in Apoe−/− mice has been shown to notably reduce atherosclerosis progression (Kirii et al., 2003). Here, IL1B is linked to atherosclerosis.